Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in: Quality of Life Research 1/2018

05.09.2017 | Commentary

Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al

verfasst von: Karin Ribi, Alan Coates, Lynette Blacher, Meredith M. Regan, Richard D. Gelber, Jürg Bernhard

Erschienen in: Quality of Life Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

In 2016, a publication on health-related quality of life (HRQoL) assessment in patients with breast cancer reported on a systematic and standardized comparison of available instruments using the evaluation measures of patient-reported-outcomes (EMPRO) tool [1]. In this review, eight HRQoL measures were compared including 32 studies reporting on psychometric properties or the validation process. One of the instruments included in this review is the International Breast Cancer Study Group (IBCSG) quality of life (QoL) Core Form [2]. Although we are pleased that the IBCSG QoL Core Form could be recommended for assessing health-related quality of life in breast cancer [1], the description of specific characteristics of the IBCSG form and the rating of this instrument based on EMPRO [3] requires clarification and further discussion of the development research overlooked during the rating. Although Maratia et al. [1] conducted a predefined systematic search and selection of papers, they used only a summary paper that was published in 1997 to describe the IBCSG approach [2]. More detailed psychometric data for the IBCSG QoL Core Form have been published in many other studies as described in the following paragraphs. …
Literatur
1.
Maratia, S., Cedillo, S., & Rejas, J. (2016). Assessing health-related quality of life in patients with breast cancer: A systematic and standardized comparison of available instruments using the EMPRO tool. Quality of Life Research, 25(10), 2467–2480. doi:10.​1007/​s11136-016-1284-8.CrossRefPubMed
2.
Bernhard, J., Hürny, C., Coates, A. S., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1997). Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Annals of Oncology, 8(9), 825–835.CrossRefPubMed
3.
4.
Bernhard, J., Peterson, H. F., Coates, A. S., Gusset, H., Isley, M., Hinkle, R., et al. (1998). Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: Practical issues and factors associated with missing data. Statistics in Medicine, 17(5–7), 587–601.CrossRefPubMed
5.
Butow, P., Coates, A., Dunn, S., Bernhard, J., & Hurny, C. (1991). On the receiving end. IV: Validation of quality of life indicators. Annals of Oncology, 2(8), 597–603.CrossRefPubMed
6.
Bernhard, J., Sullivan, M., Hurny, C., Coates, A. S., & Rudenstam, C. M. (2001). Clinical relevance of single item quality of life indicators in cancer clinical trials. British Journal of Cancer, 84(9), 1156–1165.CrossRefPubMedPubMedCentral
7.
Hurny, C., Bernhard, J., Coates, A., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1996). Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Medical Care, 34(3), 234–248.CrossRefPubMed
8.
Hurny, C., Bernhard, J., Bacchi, M., van Wegberg, B., Tomamichel, M., Spek, U., et al. (1993). The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Supportive Care in Cancer, 1(4), 200–208.CrossRefPubMed
9.
Hürny, C., van Wegberg, B., Bacchi, M., Bernhard, J., Thürlimann, B., Ral, O., et al. (1998). Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for cancer clinical trials. British Journal of Cancer, 77, 985–991.CrossRefPubMed
10.
Michels, F. A. S., Latorre, R. D. O., & Maciel, M. S. (2010). Validation, reliability, and comprehension of the IBCSG quality of life questionnaire specifi to Breast Cancer. Applied Cancer Research, 30(4), 348–352.
11.
Hurny, C., Bernhard, J., Gelber, R. D., Coates, A., Castiglione, M., Isley, M., et al. (1992). Quality of life measures for patients receiving adjuvant therapy for breast cancer: An international trial. The International Breast Cancer Study Group. European Journal of Cancer, 28(1), 118–124.CrossRefPubMed
12.
Wild, D., Grove, A., Martin, M., Eremenco, S., McElroy, S., Verjee-Lorenz, A., et al. (2005). Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. Value Health, 8(2), 94–104. doi:10.​1111/​j.​1524-4733.​2005.​04054.​x.CrossRefPubMed
13.
Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., et al. (1983). On the receiving end–patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology, 19(2), 203–208.CrossRefPubMed
14.
Coates, A., Glasziou, P., & McNeil, D. (1990). On the receiving end–III. Measurement of quality of life during cancer chemotherapy. Annals of Oncology, 1(3), 213–217.CrossRefPubMed
15.
International Breast Cancer Study G, Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., et al. (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10–93. Journal of Clinical Oncology, 24(3), 337–344. doi:10.​1200/​JCO.​2005.​01.​5784.CrossRef
16.
Hurny, C., Bernhard, J., Coates, A. S., Castiglione-Gertsch, M., Peterson, H. F., Gelber, R. D., et al. (1996). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet, 347(9011), 1279–1284.
17.
Bernhard, J., Zahrieh, D., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., et al. (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British Journal of Cancer, 98(1), 25–33. doi:10.​1038/​sj.​bjc.​6604092.CrossRefPubMed
18.
Bernhard, J., Zahrieh, D., Castiglione-Gertsch, M., Hurny, C., Gelber, R. D., Forbes, J. F., et al. (2007). Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology, 25(3), 263–270.CrossRefPubMed
19.
Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., et al. (2015). Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncology, 16(7), 848–858. doi:10.​1016/​S1470-2045(15)00049-2.CrossRefPubMed
20.
Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Bellet, M., et al. (2016). Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen-alone in premenopausal women with early breast cancer: patient-reported outcome in the SOFT trial. Journal of Clinical Oncology, 34(14), 1601–1610.CrossRefPubMedPubMedCentral
21.
Bernhard, J., Castiglione-Gertsch, M., Schmitz, S. F., Thurlimann, B., Cavalli, F., Morant, R., et al. (1999). Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonal treatment. Swiss group for clinical cancer research (SAKK). European Journal of Cancer, 35(6), 913–920.CrossRefPubMed
22.
Bernhard, J., Thurlimann, B., Schmitz, S. F., Castiglione-Gertsch, M., Cavalli, F., Morant, R., et al. (1999). Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? Journal of Clinical Oncology, 17(6), 1672–1679.CrossRefPubMed
23.
Lee, C. K., Stockler, M. R., Coates, A. S., Gebski, V., Lord, S. J., & Simes, R. J. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341–1347.CrossRefPubMedPubMedCentral
24.
Coates, A., Gebski, V., Signorini, D., Murray, P., McNeil, D., Byrne, M., et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology, 10(12), 1833–1838.CrossRefPubMed
25.
Coates, A. S., Hürny, C., Peterson, H. F., Bernhard, J., Castiglione-Gertsch, M., Gelber, R. D., et al. (2000). Quality-of-life scores predict outcome in metastatic but not early breast cancer. Journal of Clinical Oncology, 18(22), 3768–3774.CrossRefPubMed
Metadaten
Titel
Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al
verfasst von
Karin Ribi
Alan Coates
Lynette Blacher
Meredith M. Regan
Richard D. Gelber
Jürg Bernhard
Publikationsdatum
05.09.2017
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 1/2018
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1695-1

Weitere Artikel der Ausgabe 1/2018

Quality of Life Research 1/2018 Zur Ausgabe

OriginalPaper

Combat exposure, emotional and physical role limitations, and substance use among male United States Army Reserve and National Guard soldiers

OriginalPaper

Assessing the measurement invariance of the Brief Multidimensional Students’ Life Satisfaction Scale in Chinese and American adolescents

OriginalPaper

Assessing responsiveness over time of the PROMIS® pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease

OriginalPaper

Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer

OriginalPaper

Perceived medication adherence barriers mediating effects between gastrointestinal symptoms and health-related quality of life in pediatric inflammatory bowel disease

OriginalPaper

Differential item functioning by language on the PROMIS® physical functioning items for children and adolescents